Changes in Plasma ACTH Levels and Corticotroph Tumor Size in Patients With Cushing's Disease During Long-term Treatment With the Glucocorticoid Receptor Antagonist Mifepristone | Zendy

Maria Fleseriu | Zendy; James W. Findling | Zendy; Christian A. Koch | Zendy; SvenMartin Schlaffer | Zendy; Michael Buchfelder | Zendy; Coleman Gross | Zendy

Open Access

Changes in Plasma ACTH Levels and Corticotroph Tumor Size in Patients With Cushing's Disease During Long-term Treatment With the Glucocorticoid Receptor Antagonist Mifepristone

Author(s) -

Maria Fleseriu,

James W. Findling,

Christian A. Koch,

SvenMartin Schlaffer,

Michael Buchfelder,

Coleman Gross

Publication year - 2014

Publication title -

the journal of clinical endocrinology and metabolism

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.206

H-Index - 353

eISSN - 1945-7197

pISSN - 0021-972X

DOI - 10.1210/jc.2014-1843

Subject(s) - mifepristone , medicine , discontinuation , antiglucocorticoid , glucocorticoid , endocrinology , cushing's disease , adrenocorticotropic hormone , magnetic resonance imaging , hormone antagonist , glucocorticoid receptor , corticotropic cell , gastroenterology , anterior pituitary , antagonist , urology , receptor , hormone , disease , radiology , pregnancy , biology , genetics

Pituitary effects of long-term therapy with mifepristone, a glucocorticoid receptor antagonist, in Cushing's disease (CD) patients are not well understood.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research